Tumor News and Research

RSS

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

Rensselaer Polytechnic Institute Professor Richard Radke is leading a new $1.4 million study to develop novel computer automation techniques that could reduce the prep time of a promising cancer-treatment technology from several hours to a few minutes.

27 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

CEVEC, Pevion Biotech sign license option agreement for transient CAP-T cell expression technology

CEVEC Pharmaceuticals, the German developer of a novel human expression system derived from amniocytes, announced today the signing of an exclusive license option agreement with Pevion Biotech, the Swiss vaccine company. The agreement enables Pevion Biotech to exclusively use CEVEC's transient CAP-T™ cell expression technology to manufacture and commercialize a protein antigen for vaccination against a widespread human infectious disease.

26 May 2010

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Silence Therapeutics plc announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).

26 May 2010

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.

25 May 2010

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Epeius Biotechnologies Corporation today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

New therapies can turn cancer into chronic disease

Two new studies suggest that the prolonged use of cancer drugs helped stunt the progress of the disease, a shift from the scheduled courses of treatment typically delivered to patients, The Wall Street Journal reports.

24 May 2010

South Dakota State University mathematicians design mathematical models to treat cancer

South Dakota State University mathematicians are helping doctors of the Mayo Clinic build mathematical models to fine-tune an innovative strategy to treat cancer.

24 May 2010

Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.

21 May 2010

Study explores genetic imbalances that give rise to childhood brain tumors

The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.

21 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Researchers discover key gene that promotes development of common kidney cancer

Researchers at Mayo Clinic's campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other cancers may turn the gene back on, providing a much-needed therapy for the difficult-to-treat cancer.

21 May 2010

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

Parents found to be carriers of a mutated form of the tumor suppressor genes known as BRCA1 and BRCA2 do not always share these test results with their children, but they may choose to discuss related information important to their own health with them. That is the result of a study conducted by an investigator at The Cancer Institute of New Jersey (CINJ) and colleagues, whose findings suggest that those parents are using the discovery of their mutation status as an opportunity for a "teachable moment" in educating their offspring about cancer risk reduction.

21 May 2010

Tumor News and Research

Modified measles virus may hold potential for treatment of medulloblastoma

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

Highlights from June 2010 issue of American Journal of Pathology

CEVEC, Pevion Biotech sign license option agreement for transient CAP-T cell expression technology

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

2010 ASCO Annual Meeting highlights new research findings on cancer

New therapies can turn cancer into chronic disease

South Dakota State University mathematicians design mathematical models to treat cancer

Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

Study explores genetic imbalances that give rise to childhood brain tumors

New therapy program serves as foundation for ongoing clinical development

Cancer Institute of New Jersey investigators target autophagy

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Researchers discover key gene that promotes development of common kidney cancer

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News